Clinical Research Directory
Browse clinical research sites, groups, and studies.
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
Sponsor: University of Arizona
Summary
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
Official title: Safety and Efficacy of Allopregnanolone (Allo) as a Regenerative Therapeutic for Alzheimer's Disease: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Clinical Trial
Key Details
Gender
All
Age Range
55 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2023-08-15
Completion Date
2027-03-18
Last Updated
2026-03-13
Healthy Volunteers
No
Interventions
Allopregnanolone
Allopregnanolone 4mg IV via 30-minute infusion, once per week.
Placebo
Normal saline solution IV via 30-minute infusion, once per week
Locations (10)
Perseverance Research Center
Scottsdale, Arizona, United States
University of Arizona / Clinical & Translational Sciences Research Center
Tucson, Arizona, United States
ATP Clinical Research
Costa Mesa, California, United States
Wake Research-PRI, LLC
Los Alamitos, California, United States
Syrentis Clinical Research
Santa Ana, California, United States
Optimus U Corporation
Miami, Florida, United States
Miami Jewish Health
Miami, Florida, United States
Combined Research Orlando
Orlando, Florida, United States
Conquest Research
Winter Park, Florida, United States
MedVadis Research
Waltham, Massachusetts, United States